MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke
Stroke
About this trial
This is an interventional treatment trial for Stroke focused on measuring Stroke, Cerebrovascular accident, Upper extremity, Cerebral Infarction, Brain Infarction, Brain Ischemia, Cerebrovascular Disorders, Cardiovascular Diseases, Nervous System Diseases, Central Nervous System Diseases
Eligibility Criteria
Inclusion Criteria:
- Ischemic or hemorrhagic stroke confirmed by MRI or CT scan
- Sub-acute subjects at least 10 days post stroke. Chronic subjects at least 6 months post stroke
- Chedoke-McMaster Stroke Assessment Stage 1-2 (arm and hand)
- Severe hemiplegia of the upper extremity defined as UE-FMA score of less than or equal to 19
- Subject is able to follow instructions
- Subject is able to sit and participate in one hour of upper limb therapy
- Anticipated to be discharged home or already at home following conventional inpatient rehabilitation
- Willing to attend outpatient therapy if chronic or late sub-acute
- Subject is able and willing to give written informed consent
- Men and women aged 18 or older
Exclusion Criteria:
- Global Aphasia
- Previous history of clinical stroke either ischemic infarct, hemorrhagic and subarachnoid bleeding
- Upper extremity injury or condition prior to stroke that limits the function of the hand or arm
- Life expectancy of less than 12 months due to other illness
- Subject has malignant skin lesion on the affected upper extremity
- Subject has history of seizure disorder and on seizure medications
- Subject has existing electrical stimulation devices (ICD, Pacemaker, Spinal Stimulation)
- Neurologic condition that may affect motor response (e.g. Parkinson's, ALS, MS)
- Subject has rash or open wound at any potential electrode site
- In the judgment of the medical provider, subject has medical complications that may interfere with the execution of the study
- Botulinum toxin (Botox) injection into affected upper extremity at least 3 months before the study or during the study
- Currently enrolled in another upper limb study
- Enrolled in the past six months in a clinical study involving drugs or biologics
Sites / Locations
- Toronto Rehab Inst, UHN
Arms of the Study
Arm 1
Experimental
MyndMove
The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.